Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

31 oct. 2017 10h35 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Phase 2b Psoriasis Study On-Track for Completion in December 2017; Company a Sponsor at Upcoming Symposium on Hidradenitis Suppurativa

BEVERLY, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report continued...
26 oct. 2017 07h30 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes

BEVERLY, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the completion of the...
24 oct. 2017 07h30 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides Development Update on Brilacidin for Inflammatory Bowel Disease

BEVERLY, Mass., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a development update...
18 oct. 2017 08h00 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals to Complete Phase 2 Trial of Brilacidin for Oral Mucositis in Cancer Patients

BEVERLY, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that all patients...
02 oct. 2017 07h00 HE | Source: Innovation Pharmaceuticals, Inc.

Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2 Trial of Brilacidin for Preventing Oral Mucositis in Cancer Patients

BEVERLY, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has...
14 sept. 2017 07h30 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial

BEVERLY, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that a new...
11 sept. 2017 11h00 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Secures New $30 Million Common Stock Purchase Agreement

BEVERLY, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the Company has...
28 août 2017 07h00 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Completes Full Patient Enrollment in Phase 2b Study of Prurisol for the Oral Treatment of Psoriasis

BEVERLY, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has met the goal...
15 août 2017 07h00 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals to Discuss Recent Positive Clinical Results in IBD and Upcoming Milestones in Oral Mucositis and Psoriasis Trials at BioCentury’s “NewsMakers” Conference

BEVERLY, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that the Company will present...
07 août 2017 06h30 HE | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis

BEVERLY, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has completed...

Page précédente